STAAR Surgical Past Earnings Performance
Past criteria checks 0/6
STAAR Surgical's earnings have been declining at an average annual rate of -19.2%, while the Medical Equipment industry saw earnings growing at 14.9% annually. Revenues have been growing at an average rate of 15.6% per year.
Key information
-19.20%
Earnings growth rate
-19.55%
EPS growth rate
Medical Equipment Industry Growth | 8.90% |
Revenue growth rate | 15.57% |
Return on equity | -20.31% |
Net Margin | -25.46% |
Last Earnings Update | 28 Mar 2025 |
Recent past performance updates
Recent updates
Is STAAR Surgical Company (NASDAQ:STAA) Trading At A 37% Discount?
Apr 05Why Investors Shouldn't Be Surprised By STAAR Surgical Company's (NASDAQ:STAA) 26% Share Price Plunge
Feb 14STAAR Surgical Q4: Ongoing Challenges In China Masks Healthy Growth Elsewhere
Feb 12STAAR Surgical: Growth Story Remains Intact Despite Some Challenges
Jan 31STAAR Surgical Company's (NASDAQ:STAA) Earnings Haven't Escaped The Attention Of Investors
Nov 29Return Trends At STAAR Surgical (NASDAQ:STAA) Aren't Appealing
Oct 24EVO ICL Technology Transforms Vision Care, Securing Major Growth And Market Share Expansion
STAAR Surgical's record sales and expansion in the diopter curve indicate strong global adoption of EVO ICL technology and potential for increased market share.STAAR Surgical: Expecting A Re-Acceleration In Growth As Investments Materialize
Sep 05Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 10STAAR Surgical Company's (NASDAQ:STAA) Popularity With Investors Is Clear
Aug 05The Returns At STAAR Surgical (NASDAQ:STAA) Aren't Growing
Jul 12Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?
May 27Market Participants Recognise STAAR Surgical Company's (NASDAQ:STAA) Revenues Pushing Shares 30% Higher
Apr 26STAAR Surgical Stock: I Don't See A Great Path Forward, Despite The Recent Surge
Apr 05STAAR Surgical (NASDAQ:STAA) Shareholders Will Want The ROCE Trajectory To Continue
Mar 25STAAR Surgical Company: Potential Buy After Long-Term Valuation Downgrade
Mar 13STAAR Surgical Company (NASDAQ:STAA) Looks Just Right With A 28% Price Jump
Mar 07Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?
Jan 31With STAAR Surgical Company (NASDAQ:STAA) It Looks Like You'll Get What You Pay For
Jan 05Returns On Capital Are Showing Encouraging Signs At STAAR Surgical (NASDAQ:STAA)
Nov 30Is There An Opportunity With STAAR Surgical Company's (NASDAQ:STAA) 21% Undervaluation?
Nov 12Is STAAR Surgical Company (NASDAQ:STAA) Potentially Undervalued?
Oct 25Returns On Capital At STAAR Surgical (NASDAQ:STAA) Have Hit The Brakes
Aug 24Are STAAR Surgical Company (NASDAQ:STAA) Investors Paying Above The Intrinsic Value?
Jul 02Is Now The Time To Look At Buying STAAR Surgical Company (NASDAQ:STAA)?
Jun 17Here's Why We Think STAAR Surgical (NASDAQ:STAA) Might Deserve Your Attention Today
May 13A Look At The Fair Value Of STAAR Surgical Company (NASDAQ:STAA)
Mar 26STAAR Surgical (NASDAQ:STAA) Is Looking To Continue Growing Its Returns On Capital
Mar 12Should You Investigate STAAR Surgical Company (NASDAQ:STAA) At US$68.56?
Feb 13Here's Why We Think STAAR Surgical (NASDAQ:STAA) Might Deserve Your Attention Today
Jan 28Calculating The Fair Value Of STAAR Surgical Company (NASDAQ:STAA)
Dec 15The Return Trends At STAAR Surgical (NASDAQ:STAA) Look Promising
Dec 01Revenue & Expenses Breakdown
How STAAR Surgical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
28 Mar 25 | 279 | -71 | 197 | 54 |
27 Dec 24 | 314 | -20 | 198 | 54 |
27 Sep 24 | 341 | 22 | 189 | 53 |
28 Jun 24 | 333 | 17 | 186 | 50 |
29 Mar 24 | 326 | 15 | 184 | 47 |
29 Dec 23 | 322 | 21 | 179 | 44 |
29 Sep 23 | 310 | 20 | 179 | 43 |
30 Jun 23 | 306 | 26 | 171 | 41 |
31 Mar 23 | 295 | 33 | 158 | 38 |
30 Dec 22 | 284 | 40 | 143 | 36 |
30 Sep 22 | 279 | 38 | 133 | 35 |
01 Jul 22 | 262 | 34 | 125 | 34 |
01 Apr 22 | 243 | 29 | 117 | 34 |
31 Dec 21 | 230 | 28 | 112 | 34 |
01 Oct 21 | 217 | 23 | 104 | 34 |
02 Jul 21 | 206 | 21 | 96 | 34 |
02 Apr 21 | 179 | 11 | 84 | 33 |
01 Jan 21 | 163 | 6 | 80 | 32 |
02 Oct 20 | 156 | 9 | 78 | 30 |
03 Jul 20 | 148 | 7 | 76 | 28 |
03 Apr 20 | 153 | 13 | 77 | 27 |
03 Jan 20 | 150 | 14 | 75 | 25 |
27 Sep 19 | 142 | 9 | 72 | 24 |
28 Jun 19 | 135 | 8 | 69 | 23 |
29 Mar 19 | 129 | 6 | 67 | 22 |
28 Dec 18 | 124 | 5 | 63 | 22 |
28 Sep 18 | 118 | 4 | 60 | 22 |
29 Jun 18 | 109 | 3 | 54 | 21 |
30 Mar 18 | 97 | 1 | 49 | 21 |
29 Dec 17 | 91 | -2 | 48 | 20 |
29 Sep 17 | 88 | -2 | 45 | 19 |
30 Jun 17 | 84 | -5 | 46 | 19 |
31 Mar 17 | 84 | -6 | 46 | 18 |
30 Dec 16 | 82 | -12 | 50 | 21 |
30 Sep 16 | 81 | -13 | 51 | 20 |
01 Jul 16 | 80 | -13 | 50 | 19 |
01 Apr 16 | 78 | -12 | 49 | 18 |
01 Jan 16 | 77 | -7 | 43 | 15 |
02 Oct 15 | 73 | -8 | 42 | 14 |
03 Jul 15 | 72 | -9 | 42 | 13 |
03 Apr 15 | 74 | -9 | 43 | 12 |
02 Jan 15 | 75 | -8 | 44 | 12 |
03 Oct 14 | 77 | -7 | 46 | 11 |
04 Jul 14 | 76 | -3 | 46 | 10 |
Quality Earnings: STAA is currently unprofitable.
Growing Profit Margin: STAA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: STAA is unprofitable, and losses have increased over the past 5 years at a rate of 19.2% per year.
Accelerating Growth: Unable to compare STAA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STAA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (15.5%).
Return on Equity
High ROE: STAA has a negative Return on Equity (-20.31%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/05/25 02:28 |
End of Day Share Price | 2025/05/23 00:00 |
Earnings | 2025/03/28 |
Annual Earnings | 2024/12/27 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
STAAR Surgical Company is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Joanne Wuensch | BMO Capital Markets U.S. (Historical) |
Michael Gorman | BTIG |
John Young | Canaccord Genuity |